AIDS Therapies (Clinical Trials)

Trial Evaluating Proleukin in Combination With HIV Therapy Announced

Published in AIDS Weekly, August 30th, 1999

Chiron Corp., Emeryville, California, announced that it is enrolling patients in its international Phase III study, called SILCAAT, evaluating the safety and effectiveness of Proleukin (aldesleukin) Interleukin-2 in combination with standard anti-HIV therapy in people living with HIV who have low CD4+ T-cell counts.

Proleukin, a recombinant form of Interleukin-2, also known as T-cell growth factor, is being administered in combination with anti-HIV therapy in people with HIV infection. This pivotal study's primary objective is to determine if intermittent cycles of Proleukin delay the progression of HIV disease compared to what is observed with anti-HIV therapy alone...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-08-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry